{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["Not provided"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2007437"],"location":["United States"],"study_start_month":["Not provided"],"keyword":["Oxaliplatin"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.","description":"The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer","dates":{"creation":"1900-01-01"},"accession":"2007437","cross_references":{"ClinicalTrials___gov":["NCT00034619"]}}